SynthesisESC heart failure2025
Right ventricle to pulmonary artery coupling as a prognostic factor in tricuspid regurgitation: A systematic review.
Synthesis in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Right ventricle to pulmonary artery coupling as a prognostic factor in tricuspid regurgitation: A systematic review.ESC heart failure · 2025Pooled it
- Precision and pragmatism: making RV-PA coupling actionable in tricuspid regurgitation.ESC heart failure · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe tricuspid regurgitation is a prevalent condition with a poor prognosis. Recent advances in transcatheter techniques resulted in a growing population of patients who are qualified for transcatheter edge-to-edge repair of tricuspid regurgitation. There is evidence that these procedures result in an improvement in heart failure symptoms and patient-reported quality of life; however, the data guiding the qualification process are scarce. The increasing volume of patients that undergo qualification for interventional TR treatment creates the need to improve the tools for risk stratification and outcome prediction. TAPSE/SPAP ratio is an echocardiographic parameter that has been recently proposed as a predictive factor for adverse outcome in various clinical settings including patients undergoing transcatheter procedures. In this systematic review, we gathered the data on the utility of this parameter in patients with significant tricuspid regurgitation. We identified five studies fulfilling the search criteria. In all of the studies, a low TAPSE/SPAP ratio was associated with worse prognosis, but the exact cutoff value remains difficult to define. In available studies, it ranged from 0.26 to 0.49 mm/mmHg. Moreover, greater severity of tricuspid regurgitation results in an underestimation of SPAP potentially reducing the usefulness of TAPSE/SPAP ratio in patients with massive and torrential TR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.